With shares of�Corning Inc.�(NYSE:GLW) trading at around $16.35, is GLW an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
C = Catalyst for the Stock�� Movement
Corning has been making new 52-week highs as of late, but is this trend sustainable? In this stock market environment, anything is possible. However, that doesn�� mean all moves are justifiable.
Corning Incorporated produces and sells specialty glasses, ceramics, and related materials worldwide. It operates through five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences.
Corning has a diverse revenue base. There is currently high demand for tablets and smartphones, Gorilla Glass has received many positive reviews, Q1 estimates were recently beat, there have been cost and efficiency improvements, revenue has increased for three consecutive years, and the stock is at a good valuation, trading at 14 times earnings, while the industry trades at 19 times earnings. However, when you look at the breakdown for the last quarter, there is good reason for caution. The only segment that showed improvement was Life Sciences. Corning is confident in future growth, but that doesn�� mean confidence will lead to actual results.
5 Best Life Sciences Stocks To Own Right Now: Rexahn Pharmaceuticals Inc (RNN)
Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.
Archexin
Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.
Serdaxin
Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.
Zoraxel
Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.
The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's just starting to move into breakout territory is Rexahn Pharmaceuticals (RNN), which is engaged in the development of novel treatments for cancer to patients. This stock has been on fire so far in 2013, with shares up sharply by 62%.
If you take a look at the chart for Rexahn Pharmaceuticals, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of 36 cents per share to its intraday high of 53 cents per share. During that uptrend, shares of RNN have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RNN into breakout territory above some near-term overhead resistance levels at 49 cents to 50 cents per share. It's worth noting that volume today is tracking in extremely strong with over 3 million shares traded, versus its three-month average action of 1.22 million shares.
Traders should now look for long-biased trades in RNN if it manages to break out above Thursday's intraday high of 53 cents per share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.22 million shares. If that breakout hits soon, then RNN will set up to re-test or possibly take out its next major overhead resistance levels at 64 cents to its 52-week high at 66 cents per share. Any high-volume move above 66 cents to 67 cents per share could then send RNN towards its next major overhead resistance levels at 81 cents per share.
Traders can look to buy RNN off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at 47 cents per share. One can also buy RNN off strength once it clears 53 cents per share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
5 Best Life Sciences Stocks To Own Right Now: Westell Technologies Inc.(WSTL)
Westell Technologies, Inc., through its subsidiaries, engages in the design, distribution, marketing, and servicing a range of broadband, digital transmission, remote monitoring, power distribution, and demarcation products used by telephone companies and other telecommunications service providers. It operates in three segments: Customer Networking Systems (CNS) equipment, Outside Plant Systems (OSP) equipment, and ConferencePlus services. The CNS equipment segment provides networking and high-speed transmissions products, such as modems, routers, versatile gateway devices, and wireless broadband home routers that allow service providers to deliver broadband services over existing copper, fiber, coax, or wireless infrastructures. The OSP segment offers next generation outdoor cabinets; enclosures; power distribution; fiber, Ethernet, and coax edge connectors; remote monitoring equipment; and DS1 and DS3 transmission plugs. This segment also markets and sells power distribu tion and remote monitoring solutions. The ConferencePlus services segment provides audio, Web, and video conferencing services to businesses and individuals. This segment sells its services directly to Fortune 1000 companies, and indirectly through its private reseller programs. The company offers its products through field sales organizations and selected distributors in the United States, as well as in Canada and Europe. Westell Technologies, Inc. was founded in 1980 and is headquartered in Aurora, Illinois.
Advisors' Opinion:- [By Rich Smith]
On Friday, the diversified manufacturer named Brian S. Cooper�to replace interim CFO Braden Waverley on May 28. Waverly will remain acting CFO until Cooper joins the company next month. Cooper comes to Federal Signal by way of smaller telecommunications equipment maker Westell Technologies (NASDAQ: WSTL ) , where he has served as CFO since 2009.
- [By Geoff Gannon]
1. Steel Excel (SXCL)
2. FormFactor (FORM)
3. Imation (IMN)
4. Tuesday Morning (TUES)
5. Pacific Biosciences (PACB)
6. Maxygen (MAXY)
7. Westell (WSTL)
8. Volt Information Sciences (VISI)
9. Yasheng Group (YHGG) - [By Rich Smith]
Late last month, the networking equipment maker had to scramble when its acting chief financial officer, Tom Minichiello, announced plans to retire on July 12 to become the new CFO at Westell Technologies (NASDAQ: WSTL ) . On Friday, though, just as the deadline was happening, Tellabs announced that it has found a replacement.
Hot High Tech Companies To Watch For 2014: Calpine Corp (CPN)
Calpine Corporation (Calpine) is an independent wholesale power producer in the United States. The Company owns and operates primarily natural gas-fired and geothermal power plants in North America and has presence in wholesale power markets in California, Texas and the Mid-Atlantic region of the United States. The Company has invested in clean power generation. It is developing, constructing, owning and operating an environmentally responsible portfolio of power plants. Its portfolio is primarily consists of two types of power generation technologies: natural gas-fired combustion turbines, which are combined-cycle plants, and renewable geothermal conventional steam turbines. The Company is a owner and operator of industrial gas turbines, as well as cogeneration power plants. The Company sells wholesale power, steam, capacity, renewable energy credits and ancillary services to its customers, including utilities, independent electric system operators, industrial and agricultural companies, retail power providers, municipalities and power marketers. It purchases natural gas and fuel oil as fuel for its power plants and engage in related natural gas transportation and storage transactions. The Company also purchases electric transmission rights to deliver power to its customers. In February 2014, the Company announced that it has completed the acquisition of a natural gas-fired, combined-cycle power plant located in Guadalupe County, 30 miles northeast of San Antonio, Texas.
As of December 31, 2011, the Company owned 93 power plants, including two under construction, with an aggregate generation capacity of approximately 28,155 megawatts and 584 megawatts under construction. Its generation capacity includes 77 natural gas-fired power plants, 15 geothermal plants and one photovoltaic solar plant. The Company is a consumer of natural gas in North America. The Company sells a substantial portion of its power and other products under power purchase agreements (PPAs) with a duration greater than ! one year.. The contracted sale of power, steam and capacity from its cogeneration power plants, combustion turbine power plants and geothermal power plants, as well as the sale of renewable energy credits (RECs), from its geothermal and solar power plants, provide a stable source of revenue. The Company produces power for sale to utilities, municipalities, retail power providers, independent electric system operators, large end-use industrial or agricultural customers or power marketers. Its cogeneration power plants produce steam for sale to customers for use in industrial or heating, ventilation and air conditioning operations. The Company provides capacity for sale to retail power providers. It provides ancillary service products to wholesale power markets. It sells RECs from its Geysers Assets in northern California, as well as from its small solar power plant in New Jersey.
The Company�� natural gas-fired power plants primarily utilize two types of design: 3,515 megawatts of simple-cycle combustion turbines and 23,043 megawatts of combined-cycle combustion turbines and a small portion from natural gas-fired steam turbines. Its Geysers Assets are a 725 megawatts fleet of 15 operating power plants in northern California. It leases the geothermal steam fields from which it extracts steam for its Geysers Assets. The Company has leasehold mineral interests in 110 leases comprising approximately 29,019 acres of federal, state and private geothermal resource lands in The Geysers region of northern California. Its leases cover one contiguous area of property that comprises approximately 45 square miles in the northwest corner of Sonoma County and southeast corner of Lake County. Across the fleet, it also has a variety of technologies, including approximately 868 megawatts of capacity from its power plants acquired in the Conectiv Acquisition which have conventional steam turbine technology. The Company also has approximately four megawatts of capacity from solar power generation technology a! t its Vine! land Solar Energy Center in New Jersey.
The Company has 24 natural gas-fired power plants, including two under construction, with the capacity to generate a total of 6,194 megawatts in the Western Electricity Coordinating Council (WECC) North American Electric Reliability Council (NERC) region, which extends from the Rocky Mountains westward. In addition, it owns and operate 15 geothermal power plants located in northern California capable of producing a total of 725 megawatts. The majority of these power plants are located in California, in the California Independent System Operator (CAISO) region; the Company also owns a power plant in Arizona and one in Oregon. The Company has 12 natural gas-fired power plants in the TRE NERC region with the capacity to generate a total of 7,239 megawatts, all of which are physically located in the ERCOT market. It has a total of 31 power plants with 7,914 megawatts of peaking capacity located in the RFC, Northeast Power Coordinating Council (NPCC) and Midwest Reliability Organization (MRO) NERC regions. The Company has 19 operating power plants with the capacity to generate a total of 4,491 megawatts in Eastern PJM. In addition, it has one operating power plant, with the capacity to generate 503 megawatts, located in Western PJM. The company has a total of eight natural gas-fired power plants with the capacity to generate a total of 1,439 megawatts in the NPCC NERC region. Five of these power plants are located in New York.
The Company has 50% ownership interests in two Canadian power plants, with the total capacity to generate 1,088 MW (544 megawatts net attributable to Calpine), located in the NPCC NERC region in Ontario, Canada. The Whitby cogeneration facility is a 50 megawatts facility located in Whitby, Ontario and the Greenfield Energy Centre is a 1,038 megawatts facility located in Courtright, Ontario. The Company has three natural gas-fired power plants with the capacity to generate a total of 1,481 megawatts operating within the M! RO NERC r! egion. The Company has one operating natural gas-fired power plant with the capacity to generate 1,134 megawatts located in the Southwest Power Pool (SPP) NERC region. SPP is an RTO approved by FERC that provides independent administration of the electric power grid. SPP manages an energy-only location based real-time wholesale energy market. The Company has 10 natural gas-fired power plants with the capacity to generate a total of 4,949 megawatts operating within the Southeastern Electric Reliability Council (SERC) and the Florida Reliability Coordinating Council (FRCC) NERC regions.
Advisors' Opinion:- [By Sean Williams]
The first risk NextEra faces is its extraordinarily high levels of debt. It's true that cash flow from electricity generation is steady, but so is the interest it pays on the $28.2 billion in debt the company carries on its balance sheet. Electric utilities don't have much choice when it comes to upgrading or expanding their operations in order to reduce their long-term operating costs other than to take on debt to fund projects. The danger is that sometimes this debt can even put previous darlings out of business. U.S. electric utility Calpine (NYSE: CPN ) , for example, was forced to declare bankruptcy in 2005, weighed down by $17 billion in debt at the time. Calpine's collapse had a lot to do with the weakness in the energy market generated by Enron's collapse a few years prior, but it has also failed to regain its luster since reemerging from bankruptcy.�
5 Best Life Sciences Stocks To Own Right Now: Nuveen Select Maturities Municipal Fund (NIM)
Nuveen Select Maturities Municipal Fund is a closed-ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is managed by Nuveen Asset Management. It invests in the fixed income markets of the United States. The fund invests primarily in municipal securities rated Baa/BBB or better. It invests in securities that provide income exempt from federal income tax. The fund employs fundamental analysis with bottom-up stock picking approach to create its portfolio. It benchmarks the performance of its portfolio against the S&P Intermediate Municipal Bond Index and the S&P National Municipal Bond Index. Nuveen Select Maturities Municipal Fund was formed on September 18, 1992 and is domiciled in the United States.
Advisors' Opinion:- [By Ning Jia]
Net interest margin (NIM): The NIM is calculated by dividing net interest income by average earning
assets. The NIM can vary with the particular business mix and risk taken.
5 Best Life Sciences Stocks To Own Right Now: Sinovac Biotech Ltd.(SVA)
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against the hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. It offers Healive, an inactivated hepatitis A vaccine; Bilive, a combination of hepatitis A and B vaccine; Anflu, a split virus influenza vaccine; and Panflu, a vaccine against the influenza A H1N1 virus. The company's pipeline vaccine candidates include a split viron vaccine, which completed Phase II clinical trials for the H5N1 influenza virus; and a SARS vaccine, which completed Phase I clinical trials for the SARS virus. In addition, its pipeline vaccine candidates that completed the pre-clinical trials comprise human vaccines for EV71, pneumococcal conjugate, haemophilus influenzae type b, meningitis, Japanese encephalitis, chickenpox, mumps, and rubella diseases, as well as rabies vaccine for humans and animals. The company markets and sell s its vaccine products directly to the provincial and municipal disease control and prevention centers. It has a patent license agreement with the National Institutes of Health; distribution agreements with LG Life Sciences, Ltd. and Glovax C.V.; and a pandemic influenza vaccine co-development agreement with the China Center for Disease Control and Prevention. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.
Advisors' Opinion:- [By Monica Gerson]
Sinovac Biotech (NASDAQ: SVA) shares touched a new 52-week high of $7.60 after the company reported unaudited Q4 results. Sinovac Biotech posted its quarterly net income of $5.8 million, or $0.10 per share, versus a year-ago net loss of $4.6 million, or $0.08 per share.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Sinovac Biotech (NASDAQ: SVA ) has received the dreaded one-star ranking.
- [By Rich Duprey]
Troubling is that it's a new presence in humans, and while that makes its spread among the populace difficult, scientists fear that it's gaining momentum. Sinovac Biotech (NASDAQ: SVA ) , which was approved to produce vaccines several years ago, jumped almost 7% yesterday as it gears up to mass produce a vaccine to combat the new threat.
No comments:
Post a Comment